Ranibizumab Injection Articles

Stock Commentary - New York week to July 3, 2006

10 July 2006

Genentech's Lucentis gets FDA approval for use in the treatment of wet AMD

10 July 2006

Novartis seeks EU approval for Lucentis

13 March 2006

Pfizer/OSI's Macugen gets OK in Europe

27 February 2006

Burrill: US biotech racked up impressive quarter to close 2005 in record fashion

16 January 2006

Genentech's Lucentis denied fast-track status

19 September 2005

Novartis/Genentech's Lucentis is first therapy to improve vision in wet-AMD

25 July 2005

Oncology and cardiovascular drugs push Novartis' 2nd-qtr results

25 July 2005

Genentech posts 39% sales rise for 2nd-qtr 2005: Rituxan and Avastin are top-earners

18 July 2005

Stock Commentary - Europe

6 June 2005

Stock Commentary - New York

6 June 2005

Positive data for Genentech/Novartis Lucentis in AMD

30 May 2005

Novartis shows off strong R&D pipeline at annual conference

31 January 2005

Biotech steadies itself for re-opening of IPO window; strong 4th qtr expected

15 September 2003

Genaera shares rise following positive findings for squalamine as AMD therapy

11 August 2003

Novartis/Genentech deal for Lucentis

7 July 2003

Showing 101-116 of 116 articles

Go to beginningPreviousNextGo to end